首页> 外文期刊>Human vaccines & immunotherapeutics. >A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults
【24h】

A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults

机译:I期,随机,受试者的术(AP)和降低成人的破伤风 - 白喉 - 无细胞植物(TDAP)增强疫苗(TDAP)增强疫苗

获取原文
获取原文并翻译 | 示例
           

摘要

Despite high vaccination coverage worldwide, pertussis has re-emerged in many countries. This randomized, controlled, observer-blind phase I study and extension study in Belgium (March 2012-June 2015) assessed safety and immunogenicity of investigational acellular pertussis vaccines containing genetically detoxified pertussis toxin (PT) (NCT01529645; NCT02382913).420 healthy adults (average age: 26.8 5.5years, 60% female) were randomized to 1 of 10 vaccine groups: 3 investigational aP vaccines (containing pertussis antigens PT, filamentous hemagglutinin [FHA] and pertactin [PRN] at different dosages), 6 investigational TdaP (additionally containing tetanus toxoid [TT] and diphtheria toxoid [DT]), and 1 TdaP comparator containing chemically inactivated PT. Antibody responses were evaluated on days 1, 8, 30, 180, 365, and approximately 3years post-booster vaccination. Cell-mediated immune responses and PT neutralization were evaluated in a subset of participants in pre-selected groups. Local and systemic adverse events (AEs), and unsolicited AEs were collected through day 7 and 30, respectively; serious AEs and AEs leading to study withdrawal were collected through day 365 post-vaccination.Antibody responses against pertussis antigens peaked at day 30 post-vaccination and then declined but remained above baseline level at approximately 3years post-vaccination. Responses to FHA and PRN were correlated to antigen dose. Antibody responses specific to PT, toxin neutralization activity and persistence induced by investigational formulations were similar or significantly higher than the licensed vaccine, despite lower PT doses. Of 15 serious AEs, none were considered vaccination-related; 1 led to study withdrawal (premature labor, day 364; aP4 group).This study confirmed the potential benefits of genetically detoxified PT antigen. All investigational study formulations were well tolerated.
机译:尽管全球覆盖覆盖率高,但佩尔特斯已经在许多国家重新出现。在比利时的随机,控制,观察者盲阶段研究和扩展研究(2015年3月 - 2015年3月)评估了含有遗传解毒毒素毒素(PT)的研究的安全性和免疫原性疫苗(NCT01529645; NCT02382913)。420健康成人(平均年龄:26.8 5.5°,60%的女性)被随机分配给10个疫苗组中的1个:3个调查AP疫苗(含有不同剂量的Pertussis抗原Pt,丝状血凝素[FHA]和临时[PRN]),6个研究TDAP(另外含有破伤风毒素[TT]和白喉类毒素[DT])和1个TDAP比较器,含有化学灭活的PT。在第1,8,30,180,365天和加强后疫苗接种后的第1,8,30,180,365和大约3年评估抗体反应。在预选组的参与者的子集中评价细胞介导的免疫应答和PT中和。通过第7天和第30天收集本地和系统性不良事件(AES)和未经请求的AES;通过第365天接种后365天收集了导致学习退出的严重AES和AES.Antibody对植物疫苗接种后第30天达到垂直的抗原的反应,然后在接种后3年的3年下降,但仍然高于基线水平。对FHA和PRN的反应与抗原剂量相关。尽管PT剂量降低,所以通过研究制剂诱导的Pt,毒素中和活性和持续性特异于Pt,毒素中和活性和持续性的抗体反应相似或显着高于持牌疫苗。 15个严重的AES,没有被认为是疫苗接种相关的; 1导致研究提取(早产,第364天; AP4组)。本研究证实了基因上解毒的PT抗原的潜在益处。所有调查研究配方均耐受良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号